Payment overview · 2025
General Payments
$505.90
25 reported records · 10 companies
Healthcare provider profile · identity verified
Aaron Lee Mills, MD
Allopathic & Osteopathic Physicians|Family Medicine · WEST PLAINS, MO · NPI 1275628349
Verified facts
What the public records show
CMS Open Payments records show Aaron Lee Mills, MD received $505.90 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.39 | 26.8% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $119.79 | 23.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.80 | 12.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.54 | 10.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.53 | 6.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.41 | 5.6% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $27.83 | 5.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.17 | 3.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.51 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.93 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $505.90 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $135.39 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $119.79 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.80 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $60.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.54 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.41 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.41 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 255 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
255 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 604 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 554 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 479 | 102 |
| Lisinopril | Lisinopril | 419 | 93 |
| Metformin Hcl Er | Metformin Hcl | 408 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 77 |
| Furosemide | Furosemide | 315 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 281 | 71 |
| Ozempic | Semaglutide | 255 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 61 |
| Tramadol Hcl | Tramadol Hcl | 216 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 36 |
| Omeprazole | Omeprazole | 189 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 179 | 24 |
| Losartan Potassium | Losartan Potassium | 178 | 54 |
| Montelukast Sodium | Montelukast Sodium | 178 | 36 |
| Gabapentin | Gabapentin | 175 | 29 |
| Potassium Chloride | Potassium Chloride | 169 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 165 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 45 |
| Prednisone | Prednisone | 148 | 90 |
| Sertraline Hcl | Sertraline Hcl | 141 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 19 |
| Jardiance | Empagliflozin | 121 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 26 |
| Irbesartan | Irbesartan | 113 | 27 |
| Lorazepam | Lorazepam | 112 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 104 | 19 |
| Spironolactone | Spironolactone | 99 | 17 |
| Myrbetriq | Mirabegron | 98 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 98 | 17 |
| Chlorthalidone | Chlorthalidone | 95 | 22 |
| Eliquis | Apixaban | 94 | 24 |
| Famotidine | Famotidine | 90 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 23 |
| Trulicity | Dulaglutide | 89 | suppressed |
| Carvedilol | Carvedilol | 88 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 88 | 49 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 81 | 65 |
| Meloxicam | Meloxicam | 79 | 27 |
| Alprazolam | Alprazolam | 77 | 23 |
| Memantine Hcl | Memantine Hcl | 77 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | suppressed |
| Felodipine Er | Felodipine | 66 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 11 |
| Celecoxib | Celecoxib | 62 | 18 |
| Bupropion Xl | Bupropion Hcl | 61 | suppressed |
| Metformin Hcl | Metformin Hcl | 61 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 14 |
| Simvastatin | Simvastatin | 55 | 17 |
| Azithromycin | Azithromycin | 54 | 31 |
| Allopurinol | Allopurinol | 52 | 12 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 50 | 50 |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 48 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Xifaxan | Rifaximin | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Atenolol | Atenolol | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 17 |
| Finasteride | Finasteride | 42 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 38 |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Nystatin | Nystatin | 36 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 17 |
| Sotalol | Sotalol Hcl | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Roflumilast | Roflumilast | 35 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 25 |
| Cefdinir | Cefdinir | 30 | 25 |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Belsomra | Suvorexant | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Glipizide | Glipizide | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 24 |
| Nitroglycerin | Nitroglycerin | 25 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 12 |
| Repatha Pushtronex | Evolocumab | 23 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 23 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 22 | 22 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | suppressed |
| Nyamyc | Nystatin | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Bumetanide | Bumetanide | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $505.90 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FREESTYLE LIBRE, LEQVIO, MONOFERRIC, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error